Patient dosimetry in radionuclide therapy: the whys and the wherefores
暂无分享,去创建一个
[1] Jacques Ferlay,et al. Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.
[2] C S Chui,et al. A Monte Carlo approach to patient-specific dosimetry. , 1996, Medical physics.
[3] R. Monson,et al. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. , 1988, American journal of epidemiology.
[4] M. Tristam,et al. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] P. Hall,et al. Cancer risk after iodine-131 therapy for hyperthyroidism. , 1991, Journal of the National Cancer Institute.
[6] W. Yeo,et al. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial , 1999, The Lancet.
[7] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[8] Jamal Zweit,et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography , 1997, European Journal of Nuclear Medicine.
[9] M G Stabin,et al. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] B. Hsieh,et al. Radiolabelling of Lipiodol with generator-produced 188Re for hepatic tumor therapy. , 1996, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[11] G. Denardo,et al. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. , 2002, Cancer biotherapy & radiopharmaceuticals.
[12] Xiaowei Liu,et al. A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I using monte carlo simulation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] M. Sonenberg,et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.
[14] B. Wessels,et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] A A Raubitschek,et al. Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry. , 1998, Nuclear medicine and biology.
[16] K K Matthay,et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. Braunstein,et al. Thyroid stunning. , 2003, Thyroid : official journal of the American Thyroid Association.
[18] Stephen R. Thomas. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. , 2002, Cancer biotherapy & radiopharmaceuticals.
[19] J. H. Park,et al. Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. , 2002, Nuclear medicine communications.
[20] Freek J. Beekman,et al. Comparison of methods for thyroid volume estimation in patients with Graves' disease , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] M G Stabin,et al. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] G. Berg,et al. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] A. Bockisch,et al. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] F I Gilbert,et al. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] I. Mcdougall. Systemic radiation therapy with unsealed radionuclides. , 2000, Seminars in radiation oncology.
[26] G. Denardo,et al. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. , 2001, Critical reviews in oncology/hematology.
[27] Macp,et al. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[28] R. Meredith,et al. Clinical radioimmunotherapy. , 2000, Seminars in radiation oncology.
[29] M. Flower,et al. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study , 2005, European Journal of Nuclear Medicine.
[30] S. Clarke,et al. Radionuclide therapy of the thyroid , 2004, European Journal of Nuclear Medicine.
[31] P. Ladenson,et al. Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma , 1998, Annals of Internal Medicine.
[32] C. Hoefnagel. Radionuclide therapy revisited , 2005, European Journal of Nuclear Medicine.
[33] H. Thierens,et al. Thyroid uptake and radiation dose after 131I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[34] K. F. Eckerman,et al. Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn , 1987 .
[35] M. Flower,et al. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. , 2002, Physics in medicine and biology.
[36] D. Guyader,et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] R. Meredith. Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response. , 2002, Cancer biotherapy & radiopharmaceuticals.
[38] E. Potchen. Radioactive Nuclides in Medicine and Biology , 1969 .
[39] P. Voûte,et al. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.